THU0393 The clinical observational study of adult onset still’s disease in a large cohort of korean patients
Identifieur interne : 002791 ( Istex/Corpus ); précédent : 002790; suivant : 002792THU0393 The clinical observational study of adult onset still’s disease in a large cohort of korean patients
Auteurs : J. J. Kim ; K. H. Jung ; Y. B. Joo ; C. B. Choi ; Y. K. Sung ; J. B. Jun ; T. H. Kim ; S. C. Bae ; D. H. YooSource :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2013-06.
English descriptors
- Teeft :
Abstract
Background Adult onset Still’s disease (AOSD) is a rare inflammatory disorder of unknown etiology that classified into three patterns. The treatment of AOSD has been empirical and the information predicted outcome is lack. Objectives The objective of this study is to evaluate the clinical features and responses to therapy in Korean AOSD patients. Methods We retrospectively reviewed medical records of one hundred thirty-seven Korean patients with AOSD satisfied Yamaguchi’s criteria at one tertiary hospital from 2005 to 2011. Results 83.3% was female, and the average age of diagnosis is 37.1 years old. Median period of follow-up is 59.0 months. Thirty-seven patients (27.0%) are monocyclic, sixty-eight patients (49.6%) are polycyclic and thirty-two patients (23.4%) are chronic articular pattern. Clinical manifestations were: fever 89.8%, arthritis 66.4%,evanescent rash 62.8%, abnormal liver function test 62.8%, leukocytosis 55.3%, hyperferritinemia 43.1%, myalgia 38% and sore throat 35.8 et al. There was no correlation between disease pattern and clinical manifestations except level of serum ferritin between monocyclic and polycyclic pattern. Average of modified Pouchot’s score at disease onset was 4.9±1.7 and statistically correlated with monocyclic and polycyclic patterns. Prescriptions were: glucocorticoid (GC) 80.9%, methotrexate (MTX) 73.8%, leflunomide 34%, cyclosporine (CsA) 32.6%, hydroxychloroquine (HCQ) 26.2%, azathioprine (AZA) 5.7%, anti-TNF blockers 7.8% (etanercept 5, adalimumab 2, infliximab 6) and intravenous immunoglobulin 3.5%. Almost patients were treated with combination of GC and/or immune suppressants. Combination of MTX and GC were 18%. The rates of these combination plus additional leflunomide, CsA or HCQ were 20.3%, 17.6% and 9.5% respectively. The rates of combination were GC with CsA 7.2%, GC with HCQ 2.7%, GC with leflunomide 1.8% and GC with AZA 1.4% respectively. The response rates were GC 76.1%, MTX 70.2%, leflunomide 68.8%, CsA 52.3 and anti-TNF blocker 72.7%. Four cases made an attempt to treat with anakinra or tocilizumab. GC response was correlated with disease remission (p-value <0.017). MTX and leflunomide were effective at GC responders in polycylic and chronic articular patterns. CsA was not effective in the presence of arthritis, especially chronic articular pattern (p-value <0.008). Conclusions Polycyclic pattern of AOSD is more common in this study. Ferittin and modified Pouchot’s score could be considered as predictors of disease pattern but not sufficient. GC and MTX were effective treatments like previous studies. Additionally leflunomide could be used effectively in the presence of arthritis in combination with MTX rather than CsA. Disclosure of Interest None Declared
Url:
DOI: 10.1136/annrheumdis-2012-eular.2358
Links to Exploration step
ISTEX:6DFF564AD6B8A2127E9EB444F984CFDDB651FB5FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">THU0393 The clinical observational study of adult onset still’s disease in a large cohort of korean patients</title><author><name sortKey="Kim, J J" sort="Kim, J J" uniqKey="Kim J" first="J. J." last="Kim">J. J. Kim</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation></author><author><name sortKey="Jung, K H" sort="Jung, K H" uniqKey="Jung K" first="K. H." last="Jung">K. H. Jung</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, Center for Rheumatism, Inha University Hospital, Incheon, Korea, Republic Of</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, Center for Rheumatism, Inha University Hospital, Incheon, Korea, Republic Of</mods:affiliation></affiliation></author><author><name sortKey="Joo, Y B" sort="Joo, Y B" uniqKey="Joo Y" first="Y. B." last="Joo">Y. B. Joo</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation></author><author><name sortKey="Choi, C B" sort="Choi, C B" uniqKey="Choi C" first="C. B." last="Choi">C. B. Choi</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation></author><author><name sortKey="Sung, Y K" sort="Sung, Y K" uniqKey="Sung Y" first="Y. K." last="Sung">Y. K. Sung</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation></author><author><name sortKey="Jun, J B" sort="Jun, J B" uniqKey="Jun J" first="J. B." last="Jun">J. B. Jun</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation></author><author><name sortKey="Kim, T H" sort="Kim, T H" uniqKey="Kim T" first="T. H." last="Kim">T. H. Kim</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation></author><author><name sortKey="Bae, S C" sort="Bae, S C" uniqKey="Bae S" first="S. C." last="Bae">S. C. Bae</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation></author><author><name sortKey="Yoo, D H" sort="Yoo, D H" uniqKey="Yoo D" first="D. H." last="Yoo">D. H. Yoo</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6DFF564AD6B8A2127E9EB444F984CFDDB651FB5F</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1136/annrheumdis-2012-eular.2358</idno><idno type="url">https://api.istex.fr/ark:/67375/NVC-7L53RNRR-X/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002791</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002791</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">THU0393 The clinical observational study of adult onset still’s disease in a large cohort of korean patients</title><author><name sortKey="Kim, J J" sort="Kim, J J" uniqKey="Kim J" first="J. J." last="Kim">J. J. Kim</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation></author><author><name sortKey="Jung, K H" sort="Jung, K H" uniqKey="Jung K" first="K. H." last="Jung">K. H. Jung</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, Center for Rheumatism, Inha University Hospital, Incheon, Korea, Republic Of</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, Center for Rheumatism, Inha University Hospital, Incheon, Korea, Republic Of</mods:affiliation></affiliation></author><author><name sortKey="Joo, Y B" sort="Joo, Y B" uniqKey="Joo Y" first="Y. B." last="Joo">Y. B. Joo</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation></author><author><name sortKey="Choi, C B" sort="Choi, C B" uniqKey="Choi C" first="C. B." last="Choi">C. B. Choi</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation></author><author><name sortKey="Sung, Y K" sort="Sung, Y K" uniqKey="Sung Y" first="Y. K." last="Sung">Y. K. Sung</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation></author><author><name sortKey="Jun, J B" sort="Jun, J B" uniqKey="Jun J" first="J. B." last="Jun">J. B. Jun</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation></author><author><name sortKey="Kim, T H" sort="Kim, T H" uniqKey="Kim T" first="T. H." last="Kim">T. H. Kim</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation></author><author><name sortKey="Bae, S C" sort="Bae, S C" uniqKey="Bae S" first="S. C." last="Bae">S. C. Bae</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation></author><author><name sortKey="Yoo, D H" sort="Yoo, D H" uniqKey="Yoo D" first="D. H." last="Yoo">D. H. Yoo</name><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2013-06">2013-06</date><biblScope unit="volume">71</biblScope><biblScope unit="issue">Suppl 3</biblScope><biblScope unit="page" from="288">288</biblScope></imprint><idno type="ISSN">0003-4967</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-4967</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adalimumab</term><term>Adult onset disease</term><term>Adverse events</term><term>Aosd</term><term>Clinical features</term><term>Clinical manifestations</term><term>Disease activity</term><term>Disease pattern</term><term>Internal medicine</term><term>Macrophage activation syndrome</term><term>Novartis</term><term>Periodic syndrome</term><term>Polycyclic</term><term>Polycyclic pattern</term><term>Rheumatology</term><term>Syndrome</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Background Adult onset Still’s disease (AOSD) is a rare inflammatory disorder of unknown etiology that classified into three patterns. The treatment of AOSD has been empirical and the information predicted outcome is lack. Objectives The objective of this study is to evaluate the clinical features and responses to therapy in Korean AOSD patients. Methods We retrospectively reviewed medical records of one hundred thirty-seven Korean patients with AOSD satisfied Yamaguchi’s criteria at one tertiary hospital from 2005 to 2011. Results 83.3% was female, and the average age of diagnosis is 37.1 years old. Median period of follow-up is 59.0 months. Thirty-seven patients (27.0%) are monocyclic, sixty-eight patients (49.6%) are polycyclic and thirty-two patients (23.4%) are chronic articular pattern. Clinical manifestations were: fever 89.8%, arthritis 66.4%,evanescent rash 62.8%, abnormal liver function test 62.8%, leukocytosis 55.3%, hyperferritinemia 43.1%, myalgia 38% and sore throat 35.8 et al. There was no correlation between disease pattern and clinical manifestations except level of serum ferritin between monocyclic and polycyclic pattern. Average of modified Pouchot’s score at disease onset was 4.9±1.7 and statistically correlated with monocyclic and polycyclic patterns. Prescriptions were: glucocorticoid (GC) 80.9%, methotrexate (MTX) 73.8%, leflunomide 34%, cyclosporine (CsA) 32.6%, hydroxychloroquine (HCQ) 26.2%, azathioprine (AZA) 5.7%, anti-TNF blockers 7.8% (etanercept 5, adalimumab 2, infliximab 6) and intravenous immunoglobulin 3.5%. Almost patients were treated with combination of GC and/or immune suppressants. Combination of MTX and GC were 18%. The rates of these combination plus additional leflunomide, CsA or HCQ were 20.3%, 17.6% and 9.5% respectively. The rates of combination were GC with CsA 7.2%, GC with HCQ 2.7%, GC with leflunomide 1.8% and GC with AZA 1.4% respectively. The response rates were GC 76.1%, MTX 70.2%, leflunomide 68.8%, CsA 52.3 and anti-TNF blocker 72.7%. Four cases made an attempt to treat with anakinra or tocilizumab. GC response was correlated with disease remission (p-value <0.017). MTX and leflunomide were effective at GC responders in polycylic and chronic articular patterns. CsA was not effective in the presence of arthritis, especially chronic articular pattern (p-value <0.008). Conclusions Polycyclic pattern of AOSD is more common in this study. Ferittin and modified Pouchot’s score could be considered as predictors of disease pattern but not sufficient. GC and MTX were effective treatments like previous studies. Additionally leflunomide could be used effectively in the presence of arthritis in combination with MTX rather than CsA. Disclosure of Interest None Declared</div></front></TEI><istex><corpusName>bmj</corpusName><keywords><teeft><json:string>aosd</json:string><json:string>novartis</json:string><json:string>rheumatology</json:string><json:string>adalimumab</json:string><json:string>polycyclic</json:string><json:string>disease activity</json:string><json:string>adult onset disease</json:string><json:string>internal medicine</json:string><json:string>polycyclic pattern</json:string><json:string>periodic syndrome</json:string><json:string>clinical features</json:string><json:string>adverse events</json:string><json:string>clinical manifestations</json:string><json:string>disease pattern</json:string><json:string>macrophage activation syndrome</json:string><json:string>syndrome</json:string></teeft></keywords><author><json:item><name>J.J. Kim</name><affiliations><json:string>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</json:string><json:string>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</json:string></affiliations></json:item><json:item><name>K.H. Jung</name><affiliations><json:string>Division of Rheumatology, Department of Internal Medicine, Center for Rheumatism, Inha University Hospital, Incheon, Korea, Republic Of</json:string><json:string>Division of Rheumatology, Department of Internal Medicine, Center for Rheumatism, Inha University Hospital, Incheon, Korea, Republic Of</json:string></affiliations></json:item><json:item><name>Y.B. Joo</name><affiliations><json:string>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</json:string><json:string>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</json:string></affiliations></json:item><json:item><name>C.B. Choi</name><affiliations><json:string>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</json:string><json:string>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</json:string></affiliations></json:item><json:item><name>Y.K. Sung</name><affiliations><json:string>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</json:string><json:string>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</json:string></affiliations></json:item><json:item><name>J.B. Jun</name><affiliations><json:string>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</json:string><json:string>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</json:string></affiliations></json:item><json:item><name>T.H. Kim</name><affiliations><json:string>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</json:string><json:string>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</json:string></affiliations></json:item><json:item><name>S.C. Bae</name><affiliations><json:string>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</json:string><json:string>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</json:string></affiliations></json:item><json:item><name>D.H. Yoo</name><affiliations><json:string>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</json:string><json:string>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</json:string></affiliations></json:item></author><articleId><json:string>annrheumdis-2012-eular.2358</json:string></articleId><arkIstex>ark:/67375/NVC-7L53RNRR-X</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>abstract</json:string></originalGenre><abstract>Background Adult onset Still’s disease (AOSD) is a rare inflammatory disorder of unknown etiology that classified into three patterns. The treatment of AOSD has been empirical and the information predicted outcome is lack. Objectives The objective of this study is to evaluate the clinical features and responses to therapy in Korean AOSD patients. Methods We retrospectively reviewed medical records of one hundred thirty-seven Korean patients with AOSD satisfied Yamaguchi’s criteria at one tertiary hospital from 2005 to 2011. Results 83.3% was female, and the average age of diagnosis is 37.1 years old. Median period of follow-up is 59.0 months. Thirty-seven patients (27.0%) are monocyclic, sixty-eight patients (49.6%) are polycyclic and thirty-two patients (23.4%) are chronic articular pattern. Clinical manifestations were: fever 89.8%, arthritis 66.4%,evanescent rash 62.8%, abnormal liver function test 62.8%, leukocytosis 55.3%, hyperferritinemia 43.1%, myalgia 38% and sore throat 35.8 et al. There was no correlation between disease pattern and clinical manifestations except level of serum ferritin between monocyclic and polycyclic pattern. Average of modified Pouchot’s score at disease onset was 4.9±1.7 and statistically correlated with monocyclic and polycyclic patterns. Prescriptions were: glucocorticoid (GC) 80.9%, methotrexate (MTX) 73.8%, leflunomide 34%, cyclosporine (CsA) 32.6%, hydroxychloroquine (HCQ) 26.2%, azathioprine (AZA) 5.7%, anti-TNF blockers 7.8% (etanercept 5, adalimumab 2, infliximab 6) and intravenous immunoglobulin 3.5%. Almost patients were treated with combination of GC and/or immune suppressants. Combination of MTX and GC were 18%. The rates of these combination plus additional leflunomide, CsA or HCQ were 20.3%, 17.6% and 9.5% respectively. The rates of combination were GC with CsA 7.2%, GC with HCQ 2.7%, GC with leflunomide 1.8% and GC with AZA 1.4% respectively. The response rates were GC 76.1%, MTX 70.2%, leflunomide 68.8%, CsA 52.3 and anti-TNF blocker 72.7%. Four cases made an attempt to treat with anakinra or tocilizumab. GC response was correlated with disease remission (p-value >0.017). MTX and leflunomide were effective at GC responders in polycylic and chronic articular patterns. CsA was not effective in the presence of arthritis, especially chronic articular pattern (p-value >0.008). Conclusions Polycyclic pattern of AOSD is more common in this study. Ferittin and modified Pouchot’s score could be considered as predictors of disease pattern but not sufficient. GC and MTX were effective treatments like previous studies. Additionally leflunomide could be used effectively in the presence of arthritis in combination with MTX rather than CsA. Disclosure of Interest None Declared</abstract><qualityIndicators><score>6.403</score><pdfWordCount>1403</pdfWordCount><pdfCharCount>8787</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>1</pdfPageCount><pdfPageSize>595 x 842 pts (A4)</pdfPageSize><refBibsNative>false</refBibsNative><abstractWordCount>395</abstractWordCount><abstractCharCount>2759</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>THU0393 The clinical observational study of adult onset still’s disease in a large cohort of korean patients</title><genre><json:string>abstract</json:string></genre><host><title>Annals of the Rheumatic Diseases</title><language><json:string>unknown</json:string></language><issn><json:string>0003-4967</json:string></issn><eissn><json:string>1468-2060</json:string></eissn><publisherId><json:string>ard</json:string></publisherId><volume>71</volume><issue>Suppl 3</issue><pages><first>288</first></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Poster Presentations</value></json:item><json:item><value>Posters</value></json:item><json:item><value>Other orphan diseases</value></json:item></subject></host><namedEntities><unitex><date><json:string>2013</json:string></date><geogName></geogName><orgName><json:string>Department of Pediatrics, University Hospital Tuebingen, Tuebingen, Germany</json:string><json:string>University of Amsterdam</json:string><json:string>University of North Carolina</json:string><json:string>United States Background</json:string><json:string>Infectious Diseases Teaching Hospital Cluj</json:string><json:string>Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</json:string><json:string>Division of Rheumatology</json:string><json:string>Academic Medical Center</json:string><json:string>Department of Internal Medicine, Center for Rheumatism, Inha University Hospital, Incheon, Korea, Republic Of Background</json:string><json:string>University of California</json:string><json:string>Municipal Teaching Hospital Cluj, Cluj-Napoca, Romania Background</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>J. Kuemmerle</json:string><json:string>P. Simon</json:string><json:string>J.J. Kim</json:string><json:string>H. Tilson</json:string><json:string>S.C. Bae</json:string><json:string>P. Hawkins</json:string><json:string>H. Hoffman</json:string><json:string>L.O. Damian</json:string><json:string>L. Ghib</json:string><json:string>T. van der Poll</json:string><json:string>U. Walker</json:string><json:string>T.H. Kim</json:string><json:string>I. Felea</json:string><json:string>Y.K. Sung</json:string><json:string>K.H. Jung</json:string><json:string>J.B. Jun</json:string><json:string>D.H. Yoo</json:string><json:string>S. Rednic</json:string><json:string>Y.B. Joo</json:string><json:string>C.B. Choi</json:string><json:string>R. Mocanu</json:string><json:string>M. Lupse</json:string><json:string>C. Bodolea</json:string></persName><placeName><json:string>Yamaguchi</json:string><json:string>San Diego</json:string><json:string>Switzerland</json:string><json:string>United States</json:string><json:string>Basel</json:string><json:string>Amsterdam</json:string><json:string>United Kingdom</json:string><json:string>Netherlands</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Dec 2009</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/NVC-7L53RNRR-X</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - rheumatology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - arthritis & rheumatology</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - General Biochemistry, Genetics and Molecular Biology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Immunology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Immunology and Allergy</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Rheumatology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2013</publicationDate><copyrightDate>2013</copyrightDate><doi><json:string>10.1136/annrheumdis-2012-eular.2358</json:string></doi><id>6DFF564AD6B8A2127E9EB444F984CFDDB651FB5F</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-7L53RNRR-X/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-7L53RNRR-X/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/NVC-7L53RNRR-X/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">THU0393 The clinical observational study of adult onset still’s disease in a large cohort of korean patients</title><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://publisher-list.data.istex.fr">BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><availability><licence><p>© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</p></availability><date>2013</date></publicationStmt><notesStmt><note type="abstract" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-HPN7T1Q2-R">abstract</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">THU0393 The clinical observational study of adult onset still’s disease in a large cohort of korean patients</title><author xml:id="author-0000"><persName><forename type="first">J.J.</forename><surname>Kim</surname></persName><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation></author><author xml:id="author-0001"><persName><forename type="first">K.H.</forename><surname>Jung</surname></persName><affiliation>Division of Rheumatology, Department of Internal Medicine, Center for Rheumatism, Inha University Hospital, Incheon, Korea, Republic Of</affiliation><affiliation>Division of Rheumatology, Department of Internal Medicine, Center for Rheumatism, Inha University Hospital, Incheon, Korea, Republic Of</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Y.B.</forename><surname>Joo</surname></persName><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation></author><author xml:id="author-0003"><persName><forename type="first">C.B.</forename><surname>Choi</surname></persName><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Y.K.</forename><surname>Sung</surname></persName><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation></author><author xml:id="author-0005"><persName><forename type="first">J.B.</forename><surname>Jun</surname></persName><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation></author><author xml:id="author-0006"><persName><forename type="first">T.H.</forename><surname>Kim</surname></persName><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation></author><author xml:id="author-0007"><persName><forename type="first">S.C.</forename><surname>Bae</surname></persName><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation></author><author xml:id="author-0008"><persName><forename type="first">D.H.</forename><surname>Yoo</surname></persName><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation></author><idno type="istex">6DFF564AD6B8A2127E9EB444F984CFDDB651FB5F</idno><idno type="ark">ark:/67375/NVC-7L53RNRR-X</idno><idno type="DOI">10.1136/annrheumdis-2012-eular.2358</idno><idno type="href">annrheumdis-71-288-2.pdf</idno><idno type="article-id">annrheumdis-2012-eular.2358</idno><idno type="local">annrheumdis;71/Suppl_3/288-b</idno></analytic><monogr><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="pISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><idno type="publisher-id">ard</idno><idno type="PublisherID-hwp">annrheumdis</idno><idno type="PublisherID-nlm-ta">Ann Rheum Dis</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2013-06"></date><biblScope unit="volume">71</biblScope><biblScope unit="issue">Suppl 3</biblScope><biblScope unit="page" from="288">288</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2013</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Background Adult onset Still’s disease (AOSD) is a rare inflammatory disorder of unknown etiology that classified into three patterns. The treatment of AOSD has been empirical and the information predicted outcome is lack. Objectives The objective of this study is to evaluate the clinical features and responses to therapy in Korean AOSD patients. Methods We retrospectively reviewed medical records of one hundred thirty-seven Korean patients with AOSD satisfied Yamaguchi’s criteria at one tertiary hospital from 2005 to 2011. Results 83.3% was female, and the average age of diagnosis is 37.1 years old. Median period of follow-up is 59.0 months. Thirty-seven patients (27.0%) are monocyclic, sixty-eight patients (49.6%) are polycyclic and thirty-two patients (23.4%) are chronic articular pattern. Clinical manifestations were: fever 89.8%, arthritis 66.4%,evanescent rash 62.8%, abnormal liver function test 62.8%, leukocytosis 55.3%, hyperferritinemia 43.1%, myalgia 38% and sore throat 35.8 et al. There was no correlation between disease pattern and clinical manifestations except level of serum ferritin between monocyclic and polycyclic pattern. Average of modified Pouchot’s score at disease onset was 4.9±1.7 and statistically correlated with monocyclic and polycyclic patterns. Prescriptions were: glucocorticoid (GC) 80.9%, methotrexate (MTX) 73.8%, leflunomide 34%, cyclosporine (CsA) 32.6%, hydroxychloroquine (HCQ) 26.2%, azathioprine (AZA) 5.7%, anti-TNF blockers 7.8% (etanercept 5, adalimumab 2, infliximab 6) and intravenous immunoglobulin 3.5%. Almost patients were treated with combination of GC and/or immune suppressants. Combination of MTX and GC were 18%. The rates of these combination plus additional leflunomide, CsA or HCQ were 20.3%, 17.6% and 9.5% respectively. The rates of combination were GC with CsA 7.2%, GC with HCQ 2.7%, GC with leflunomide 1.8% and GC with AZA 1.4% respectively. The response rates were GC 76.1%, MTX 70.2%, leflunomide 68.8%, CsA 52.3 and anti-TNF blocker 72.7%. Four cases made an attempt to treat with anakinra or tocilizumab. GC response was correlated with disease remission (p-value <0.017). MTX and leflunomide were effective at GC responders in polycylic and chronic articular patterns. CsA was not effective in the presence of arthritis, especially chronic articular pattern (p-value <0.008). Conclusions Polycyclic pattern of AOSD is more common in this study. Ferittin and modified Pouchot’s score could be considered as predictors of disease pattern but not sufficient. GC and MTX were effective treatments like previous studies. Additionally leflunomide could be used effectively in the presence of arthritis in combination with MTX rather than CsA. Disclosure of Interest None Declared</p></abstract><textClass><keywords scheme="Journal Subject"><list><head></head><item><term>Poster Presentations</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head></head><item><term>Posters</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head></head><item><term>Other orphan diseases</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2013-06">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2017-10-17">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-7L53RNRR-X/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus bmj" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="no"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" URI="archivearticle.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="abstract" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="hwp">annrheumdis</journal-id><journal-id journal-id-type="nlm-ta">Ann Rheum Dis</journal-id><journal-id journal-id-type="publisher-id">ard</journal-id><journal-title>Annals of the Rheumatic Diseases</journal-title><abbrev-journal-title abbrev-type="publisher">Ann Rheum Dis</abbrev-journal-title><abbrev-journal-title>Ann Rheum Dis</abbrev-journal-title><issn pub-type="ppub">0003-4967</issn><issn pub-type="epub">1468-2060</issn><publisher><publisher-name>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">annrheumdis-2012-eular.2358</article-id><article-id pub-id-type="doi">10.1136/annrheumdis-2012-eular.2358</article-id><article-id pub-id-type="other">annrheumdis;71/Suppl_3/288-b</article-id><article-id pub-id-type="other">annrheumdis;annrheumdis-2012-eular.2358</article-id><article-id pub-id-type="other">288.2</article-id><article-id pub-id-type="other">annrheumdis-2012-eular.2358</article-id><article-categories><subj-group subj-group-type="heading"><subject>Scientific Abstracts</subject><subj-group><subject>Poster Presentations</subject><subj-group><subject>Posters</subject><subj-group><subject>Other orphan diseases</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>THU0393 The clinical observational study of adult onset still’s disease in a large cohort of korean patients</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kim</surname><given-names>J.J.</given-names></name><xref ref-type="aff" rid="AFF_1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jung</surname><given-names>K.H.</given-names></name><xref ref-type="aff" rid="AFF_2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Joo</surname><given-names>Y.B.</given-names></name><xref ref-type="aff" rid="AFF_1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Choi</surname><given-names>C.B.</given-names></name><xref ref-type="aff" rid="AFF_1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sung</surname><given-names>Y.K.</given-names></name><xref ref-type="aff" rid="AFF_1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jun</surname><given-names>J.B.</given-names></name><xref ref-type="aff" rid="AFF_1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kim</surname><given-names>T.H.</given-names></name><xref ref-type="aff" rid="AFF_1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bae</surname><given-names>S.C.</given-names></name><xref ref-type="aff" rid="AFF_1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yoo</surname><given-names>D.H.</given-names></name><xref ref-type="aff" rid="AFF_1"><sup>1</sup></xref></contrib></contrib-group><aff id="AFF_1"><sup>1</sup>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul
</aff><aff id="AFF_2"><sup>2</sup>Division of Rheumatology, Department of Internal Medicine, Center for Rheumatism, Inha University Hospital, Incheon, Korea, Republic Of
</aff><pub-date pub-type="ppub"><month>6</month><year>2013</year></pub-date><volume>71</volume><volume-id pub-id-type="other">71</volume-id><volume-id pub-id-type="other">71</volume-id><issue>Suppl 3</issue><issue-id pub-id-type="other">annrheumdis;71/Suppl_3</issue-id><issue-id pub-id-type="other" content-type="supplement">Suppl_3</issue-id><issue-id pub-id-type="other">71/Suppl_3</issue-id><issue-title>Annual European Congress of Rheumatology EULAR abstracts 2012, 6 – 9 June 2012, Berlin, Germany</issue-title><fpage seq="2">288</fpage><permissions><copyright-statement>© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</copyright-statement><copyright-year>2013</copyright-year></permissions><self-uri content-type="pdf" xlink:role="full-text" xlink:href="annrheumdis-71-288-2.pdf"></self-uri><abstract><sec><title>Background</title><p>Adult onset Still’s disease (AOSD) is a rare inflammatory disorder of unknown etiology that classified into three patterns. The treatment of AOSD has been empirical and the information predicted outcome is lack.</p></sec><sec><title>Objectives</title><p>The objective of this study is to evaluate the clinical features and responses to therapy in Korean AOSD patients.</p></sec><sec><title>Methods</title><p>We retrospectively reviewed medical records of one hundred thirty-seven Korean patients with AOSD satisfied Yamaguchi’s criteria at one tertiary hospital from 2005 to 2011.</p></sec><sec><title>Results</title><p>83.3% was female, and the average age of diagnosis is 37.1 years old. Median period of follow-up is 59.0 months. Thirty-seven patients (27.0%) are monocyclic, sixty-eight patients (49.6%) are polycyclic and thirty-two patients (23.4%) are chronic articular pattern. Clinical manifestations were: fever 89.8%, arthritis 66.4%,evanescent rash 62.8%, abnormal liver function test 62.8%, leukocytosis 55.3%, hyperferritinemia 43.1%, myalgia 38% and sore throat 35.8 et al. There was no correlation between disease pattern and clinical manifestations except level of serum ferritin between monocyclic and polycyclic pattern. Average of modified Pouchot’s score at disease onset was 4.9±1.7 and statistically correlated with monocyclic and polycyclic patterns. Prescriptions were: glucocorticoid (GC) 80.9%, methotrexate (MTX) 73.8%, leflunomide 34%, cyclosporine (CsA) 32.6%, hydroxychloroquine (HCQ) 26.2%, azathioprine (AZA) 5.7%, anti-TNF blockers 7.8% (etanercept 5, adalimumab 2, infliximab 6) and intravenous immunoglobulin 3.5%. Almost patients were treated with combination of GC and/or immune suppressants. Combination of MTX and GC were 18%. The rates of these combination plus additional leflunomide, CsA or HCQ were 20.3%, 17.6% and 9.5% respectively. The rates of combination were GC with CsA 7.2%, GC with HCQ 2.7%, GC with leflunomide 1.8% and GC with AZA 1.4% respectively. The response rates were GC 76.1%, MTX 70.2%, leflunomide 68.8%, CsA 52.3 and anti-TNF blocker 72.7%. Four cases made an attempt to treat with anakinra or tocilizumab. GC response was correlated with disease remission (p-value <0.017). MTX and leflunomide were effective at GC responders in polycylic and chronic articular patterns. CsA was not effective in the presence of arthritis, especially chronic articular pattern (p-value <0.008).</p></sec><sec><title>Conclusions</title><p>Polycyclic pattern of AOSD is more common in this study. Ferittin and modified Pouchot’s score could be considered as predictors of disease pattern but not sufficient. GC and MTX were effective treatments like previous studies. Additionally leflunomide could be used effectively in the presence of arthritis in combination with MTX rather than CsA.</p></sec><sec><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>THU0393 The clinical observational study of adult onset still’s disease in a large cohort of korean patients</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>THU0393 The clinical observational study of adult onset still’s disease in a large cohort of korean patients</title></titleInfo><name type="personal"><namePart type="given">J.J.</namePart><namePart type="family">Kim</namePart><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.H.</namePart><namePart type="family">Jung</namePart><affiliation>Division of Rheumatology, Department of Internal Medicine, Center for Rheumatism, Inha University Hospital, Incheon, Korea, Republic Of</affiliation><affiliation>Division of Rheumatology, Department of Internal Medicine, Center for Rheumatism, Inha University Hospital, Incheon, Korea, Republic Of</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y.B.</namePart><namePart type="family">Joo</namePart><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.B.</namePart><namePart type="family">Choi</namePart><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y.K.</namePart><namePart type="family">Sung</namePart><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.B.</namePart><namePart type="family">Jun</namePart><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.H.</namePart><namePart type="family">Kim</namePart><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.C.</namePart><namePart type="family">Bae</namePart><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.H.</namePart><namePart type="family">Yoo</namePart><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><affiliation>Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="abstract" displayLabel="abstract" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-HPN7T1Q2-R">abstract</genre><originInfo><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><dateIssued encoding="w3cdtf">2013-06</dateIssued><copyrightDate encoding="w3cdtf">2013</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract>Background Adult onset Still’s disease (AOSD) is a rare inflammatory disorder of unknown etiology that classified into three patterns. The treatment of AOSD has been empirical and the information predicted outcome is lack. Objectives The objective of this study is to evaluate the clinical features and responses to therapy in Korean AOSD patients. Methods We retrospectively reviewed medical records of one hundred thirty-seven Korean patients with AOSD satisfied Yamaguchi’s criteria at one tertiary hospital from 2005 to 2011. Results 83.3% was female, and the average age of diagnosis is 37.1 years old. Median period of follow-up is 59.0 months. Thirty-seven patients (27.0%) are monocyclic, sixty-eight patients (49.6%) are polycyclic and thirty-two patients (23.4%) are chronic articular pattern. Clinical manifestations were: fever 89.8%, arthritis 66.4%,evanescent rash 62.8%, abnormal liver function test 62.8%, leukocytosis 55.3%, hyperferritinemia 43.1%, myalgia 38% and sore throat 35.8 et al. There was no correlation between disease pattern and clinical manifestations except level of serum ferritin between monocyclic and polycyclic pattern. Average of modified Pouchot’s score at disease onset was 4.9±1.7 and statistically correlated with monocyclic and polycyclic patterns. Prescriptions were: glucocorticoid (GC) 80.9%, methotrexate (MTX) 73.8%, leflunomide 34%, cyclosporine (CsA) 32.6%, hydroxychloroquine (HCQ) 26.2%, azathioprine (AZA) 5.7%, anti-TNF blockers 7.8% (etanercept 5, adalimumab 2, infliximab 6) and intravenous immunoglobulin 3.5%. Almost patients were treated with combination of GC and/or immune suppressants. Combination of MTX and GC were 18%. The rates of these combination plus additional leflunomide, CsA or HCQ were 20.3%, 17.6% and 9.5% respectively. The rates of combination were GC with CsA 7.2%, GC with HCQ 2.7%, GC with leflunomide 1.8% and GC with AZA 1.4% respectively. The response rates were GC 76.1%, MTX 70.2%, leflunomide 68.8%, CsA 52.3 and anti-TNF blocker 72.7%. Four cases made an attempt to treat with anakinra or tocilizumab. GC response was correlated with disease remission (p-value <0.017). MTX and leflunomide were effective at GC responders in polycylic and chronic articular patterns. CsA was not effective in the presence of arthritis, especially chronic articular pattern (p-value <0.008). Conclusions Polycyclic pattern of AOSD is more common in this study. Ferittin and modified Pouchot’s score could be considered as predictors of disease pattern but not sufficient. GC and MTX were effective treatments like previous studies. Additionally leflunomide could be used effectively in the presence of arthritis in combination with MTX rather than CsA. Disclosure of Interest None Declared</abstract><relatedItem type="host"><titleInfo><title>Annals of the Rheumatic Diseases</title></titleInfo><titleInfo type="abbreviated"><title>Ann Rheum Dis</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><topic>Poster Presentations</topic></subject><subject><topic>Posters</topic></subject><subject><topic>Other orphan diseases</topic></subject><identifier type="ISSN">0003-4967</identifier><identifier type="eISSN">1468-2060</identifier><identifier type="PublisherID">ard</identifier><identifier type="PublisherID-hwp">annrheumdis</identifier><identifier type="PublisherID-nlm-ta">Ann Rheum Dis</identifier><part><date>2013</date><detail type="title"><title>Annual European Congress of Rheumatology EULAR abstracts 2012, 6 – 9 June 2012, Berlin, Germany</title></detail><detail type="volume"><caption>vol.</caption><number>71</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 3</number></detail><extent unit="pages"><start>288</start></extent></part></relatedItem><identifier type="istex">6DFF564AD6B8A2127E9EB444F984CFDDB651FB5F</identifier><identifier type="ark">ark:/67375/NVC-7L53RNRR-X</identifier><identifier type="DOI">10.1136/annrheumdis-2012-eular.2358</identifier><identifier type="href">annrheumdis-71-288-2.pdf</identifier><identifier type="ArticleID">annrheumdis-2012-eular.2358</identifier><identifier type="local">annrheumdis;71/Suppl_3/288-b</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</recordContentSource><recordOrigin>© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-7L53RNRR-X/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002791 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002791 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:6DFF564AD6B8A2127E9EB444F984CFDDB651FB5F
|texte= THU0393 The clinical observational study of adult onset still’s disease in a large cohort of korean patients
}}
| This area was generated with Dilib version V0.6.33. |  |